BRANFORD, Conn. and NESS ZIONA, Israel, Sept. 02, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced Jonathan Solomon, Chief Executive Officer, will be presenting at three upcoming virtual investor events in September.
Presentation Details:
Event: H.C. Wainwright 23rd Annual Global Investments Conference
Date: Monday, Sept. 13, 2021
Time: 7:00 a.m. EDT
Event: Oppenheimer Virtual Fall Healthcare Life Science & MedTech Summit
Date: Monday, Sept. 20, 2021
Time: 1:15 – 1:55 p.m. EDT
Event: Cantor 2021 Virtual Global Healthcare Conference
Date: Thursday, Sept. 30, 2021
Time: 11:20 a.m. EDT
Live webcasts of the three presentations will be accessible through the Investors section of the Company’s website at https://ir.biomx.com/news-events/ir-calendar. Following the events, the webcasts will be archived on the BiomX website.
About BiomX
BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as target bacteria in the treatment of chronic diseases, such as inflammatory bowel disease, primary sclerosing cholangitis, cystic fibrosis, atopic dermatitis and colorectal cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.
Additional information is available at www.biomx.com, the content of which does not form a part of this press release.
BiomX, Inc.
Assaf Oron
Chief Business Officer
+972 (54) 222-8901
assafo@biomx.com
Investors:
John Mullaly
LifeSci Advisors, LLC
(617) 429-3548
jmullaly@lifesciadvisors.com
Source: BiomX Inc
